Sirolimus (rapamycin)-based therapy in human renal transplantation -: Similar efficacy and different toxicity compared with cyclosporine

被引:727
|
作者
Groth, CG [12 ]
Bäckman, L
Morales, JM
Calne, R
Kreis, H
Lang, P
Touraine, JL
Claesson, K
Campistol, JM
Durand, D
Wramner, L
Brattström, C
Charpentier, B
机构
[1] Karolinska Inst, Huddinge Hosp, S-10401 Stockholm, Sweden
[2] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden
[3] Hosp 12 Octubre, E-28041 Madrid, Spain
[4] Addenbrookes Hosp, Cambridge, England
[5] Hop Necker Enfants Malad, Paris, France
[6] Hop Henri Mondor, F-94010 Creteil, France
[7] Hop Edouard Herriot, Lyon, France
[8] Univ Uppsala Hosp, Uppsala, Sweden
[9] Hosp Clin Barcelona, Barcelona, Spain
[10] Univ Hosp Rangueil, Toulouse, France
[11] Hop Bicetre, Kremlin Bicetre, France
[12] Huddinge Hosp, Dept Transplant Surg, S-14186 Huddinge, Sweden
关键词
D O I
10.1097/00007890-199904150-00017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Sirolimus (rapamycin) is a potent immunosuppressant with a mechanism of action different from cyclosporine (CsA) or tacrolimus. Methods. In 11 European centers, first cadaveric renal allograft recipients were randomized to CsA (n=42) or sirolimus (n=41). Dosing of these agents was concentration-controlled and open-labeled. All patients received corticosteroids and azathioprine. Results. At 12 months, graft survival (98% sirolimus vs. 90% CsA), patient survival (100% vs. 98%), and incidence of biopsy-confirmed acute rejection (41% vs. 38%) were similar, Serum creatinine was lower with sirolimus, significantly (P less than or equal to 0.05) so at 3 and 4 months, and serum uric acid and magnesium were normal. Laboratory abnormalities reported significantly more often with sirolimus included hypertriglyceridemia (51% vs. 12%), hypercholesterolemia (44% vs. 14%), thrombocytopenia (37% vs, 0%), leukopenia (39% vs. 14%), and, of lesser importance, increased liver enzymes and hypokalemia. These abnormalities improved 2 months after transplantation when the sirolimus target trough level was lowered from 30 to 15 ng/ml. Occurrence of cytomegalovirus was comparable (14% vs. 12%); incidences of herpes simplex (24% vs. 10%, P=0.08) and pneumonia (17% vs. 2%, P=0.03) were higher with sirolimus. No gingival hyperplasia was seen with sirolimus, tremor was rare, and hypertension was less frequent (17% vs. 33%), Two malignancies were observed with CsA and none with sirolimus. Conclusions. Results at 12 months suggest that sirolimus can be used as base therapy in the prophylaxis of acute renal transplant rejection, and has a safety profile that differs from CsA.
引用
收藏
页码:1036 / 1042
页数:7
相关论文
共 50 条
  • [21] Different Effect of Cyclosporine and Tacrolimus on Renal Expression of P-Glycoprotein in Human Kidney Transplantation
    Yu, X.
    Zhang, B.
    Xing, C.
    Sun, B.
    Liu, M.
    Zhang, W.
    Gu, M.
    TRANSPLANTATION PROCEEDINGS, 2008, 40 (10) : 3455 - 3459
  • [22] Renal transplant recipients receiving an immunosuppressant regimen based on sirolimus exhibit a decrease in aortic stiffness and oxidative stress as compared to cyclosporine
    Bellien, J.
    Etienne, I.
    Monteil, C.
    de Ligny, B. Hurault
    Westeel, P. F.
    Iacob, M.
    Thervet, E.
    Lebranchu, Y.
    Girardot-Seguin, S.
    Thuillez, C.
    Godin, M.
    Joannides, R.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 12 - 12
  • [23] Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants
    Petero, Virgilio G., Jr.
    Kaposztas, Zsolt
    Kahan, Barry D.
    CLINICAL TRANSPLANTATION, 2010, 24 (02) : 243 - 251
  • [24] Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy:: a multivariate analysis of results at five years
    Legendre, Christophe
    Brault, Yves
    Morales, Jose M.
    Oberbauer, Rainer
    Altieri, Paolo
    Riad, Hany
    Mahony, John
    Messina, Maria
    Pussell, Bruce
    Martinez, Javier G.
    Lelong, Magali
    Burke, James T.
    Neylan, John F.
    CLINICAL TRANSPLANTATION, 2007, 21 (03) : 330 - 336
  • [25] Renal Transplantation in Emigrants From Africa in Spain: Similar Results but Different Infectious Profile Compared With Spanish People
    Merida, E.
    Rodriguez, A.
    Hernandez, G.
    Huerta, A.
    Gonzalez, J.
    Hernandez, A.
    Gonzalez, E.
    Morales, E.
    Praga, M.
    Andres, A.
    Morales, J. M.
    TRANSPLANTATION PROCEEDINGS, 2009, 41 (06) : 2363 - 2365
  • [26] Sirolimus-based therapy with or without cyclosporine: Long-term follow-up in renal transplant patients
    Morales, JM
    Campistol, JM
    Kreis, H
    Mourad, G
    Eris, J
    Schena, FP
    Grinyo, JM
    Nanni, G
    Andres, A
    Castaing, N
    Brault, Y
    Burke, JT
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) : 693 - 696
  • [27] Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation
    Oberbauer, R
    Segoloni, G
    Campistol, JM
    Kreis, H
    Mota, A
    Lawen, J
    Russ, G
    Grinyó, JM
    Stallone, G
    Hartmann, A
    Pinto, JR
    Chapman, J
    Burke, JT
    Brault, Y
    Neylan, JF
    TRANSPLANT INTERNATIONAL, 2005, 18 (01) : 22 - 28
  • [28] Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy
    Cohen, DS
    Fisher, RA
    Shapiro, JH
    Goggins, WC
    Tawes, JW
    Mills, S
    Contos, M
    Ham, JM
    Schroeder, TJ
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (05) : 2501 - 2505
  • [29] Efficacy and safety of rapamycin-based immunosuppressive regimens with CSA preserving versus CSA withdrawal in renal transplantation
    Zhang, Yan Gang
    Lu, Yi Ping
    Teng, Dong Hai
    Wang, Li
    Li, You Ping
    TRANSPLANT INTERNATIONAL, 2007, 20 : 21 - 21
  • [30] Conversion from calcineurin-inhibitor (CNI) based immunosuppression to Sirolimus in chronic CNI toxicity after renal transplantation
    Diekmann, F
    Waiser, J
    Einecke, G
    Dragun, D
    Fritsche, L
    Neumayer, HH
    Budde, K
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 364A - 364A